All In MedTech

FDA Clearance Tracker · P150026

HEARTLIGHT ENDOSCOPIC ABLATION SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Apr 1, 2016 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Apr 1, 2016

Approved

Time to decision

246 days

Received Jul 30, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P150026
Device name
HEARTLIGHT ENDOSCOPIC ABLATION SYSTEM
Applicant location
Marlborough, MA
Received
Jul 30, 2015
Decided
Apr 1, 2016
Decision
Approved
Supplements
15 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code OAE

FDA's approval statement

As written in FDA's record.

The HeartLight® Endoscopic Ablation System is indicated for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code OAE. The earliest in FDA's data is P030031-S011, decided Feb 6, 2009.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Cardiofocus, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.